Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics develops ONS-5010/LYTENAVA, an eye treatment based on bevacizumab for wet macular degeneration. It last closed at $0.36 on Nov 17, down 8.94% on the day. OTLK reports earnings on Fri, Dec 18, 2026.
Key Stats
Last 12 monthsNot reported for this period.
From OTLK's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 18). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on OTLK in the past 90 days. The average target is $10.50, with a high of $10.50 and a low of $10.50, compared with the last close of $0.36.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 11 | Ascendiant Capital | Target raised | Buy | $10 → $10.50 |
| Jul 27 | HC Wainwright & Co. | Maintained | Hold | $1.60 |
| Jul 27 | BTIG | Upgrade | Buy | $4 |
| Jun 11 | Ascendiant Capital | Maintained | Buy | $10 |
Technical Analysis
The stock is 31% below its 20 day and 53% below its 50 day average. It is 83% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot S1 at $0.34, and the nearest resistance the Pivot at $0.37.
| RSI (14) | 27.91 | Oversold below 30 | Oversold |
| MACD | -0.04 | Below its signal line | Bearish |
| Stochastic | 6.0 | Near the bottom of its range | Oversold |
| ADX (14) | 26.1 | Trending down | |
| Williams %R | -94.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -175.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −21.6% | Change over 10 sessions | Bearish |
| ATR (14) | $0.04 | Typical daily range, 11.8% of price |
| RSI (14) | 35.08 | Weak, oversold below 30 | Neutral |
| MACD | -0.13 | Below its signal line | Bearish |
| Stochastic | 2.2 | Near the bottom of its range | Oversold |
| ADX (14) | 15.3 | No clear trend | |
| Williams %R | -97.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -92.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −45.4% | Change over 10 sessions | Bearish |
| ATR (14) | $0.19 | Typical daily range, 52.3% of price |
What happened before
See how OTLK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How OTLK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
Whale Options Flow
90DNo whale options trades in OTLK in the last 90 days.
OTLK Institutional Ownership
Full report →- ▲48 buying vs 24 selling
- ▲Held by funds +17.7 pts
- ▲Funds holding +12
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 82 | 70 | +17.1% |
| In funds' top 10 | 1 | 0 | – |
| Held by funds | 26.1% | 8.4% | +17.7 pts |
| New / increased | 26 / 22 | 27 / 20 | +2.1% |
| Reduced / sold out | 11 / 13 | 7 / 13 | +20.0% |
| Put/call ratio | 0.00 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OTLK is in one of them and how their past OTLK trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered OTLK in an article yet. Here's the latest on the wider market.
About Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company based in Iselin, New Jersey. Its main product is ONS-5010/LYTENAVA, an eye treatment based on bevacizumab, an antibody first approved for cancer and adapted for use in the eye. It is used to treat wet macular degeneration, a condition that can damage central vision. The product is approved in the European Union and the United Kingdom, where the company sells it directly, and it is under review in the United States.
- Headquarters
- Iselin, NJ


